Triple-Action antibody takes on advanced cancers
Disease control
Recruiting now
This study tests a new drug called CS2009, a tri-specific antibody that targets three proteins (PD-1, VEGFA, and CTLA-4) to fight advanced solid tumors. The trial has two phases: first, finding the safest dose, then expanding to see how well it shrinks tumors. About 660 adults wi…
Phase: PHASE1, PHASE2 • Sponsor: CStone Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 12:08 UTC